Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2002 Apr 8;86(7):1117–1123. doi: 10.1038/sj.bjc.6600151

The molecular pathology of p53 in primitive neuroectodermal tumours of the central nervous system

A S Y W Burns 1, E Jaros 2, M Cole 3, R Perry 2, A J Pearson 4, J Lunec 1
PMCID: PMC2364191  PMID: 11953859

Abstract

One hundred and one pre-treatment primary central primitive neuroectodermal tumours were analysed for the expression of p53 protein by immunohistochemistry using the monoclonal antibody DO-7. The staining intensity was classified into four groups: strong, medium, weak and negative and strong staining intensity was associated with the poorest survival. DNA sequencing of the p53 gene was performed in 28 cases representing all four staining groups. Mutations were found in only three of the strong staining tumours suggesting that DNA mutations were not common events and that in the majority of the tumours with over-expressed p53, the protein was likely to be wild-type. Results of immunohistochemistry showed a significantly positive relationship between the expression of p53 and Bax and Bcl-2 proteins, but not Waf-1. Multivariate analyses supported the prognostic value of p53 immunostaining in central primitive neuroectodermal tumours and also of age and gender of patients.

British Journal of Cancer (2002) 86, 1117–1123. DOI: 10.1038/sj/bjc/6600151 www.bjcancer.com

© 2002 Cancer Research UK

Keywords: central primitive neuroectodermal tumours, p53 protein, DNA sequencing, Waf-1, Bax, Bcl-2

Primitive neuroectodermal tumours of the central nervous system (cPNETs) account for 6–8% of all brain tumours and for 12–25% of paediatric brain tumours (Roberts et al, 1991). These malignant tumours frequently occur between the ages of 3 and 12 and between 50–70 (de Vita et al, 1982) and are sensitive to radiotherapy (Chang et al, 1969). With advances in radiotherapy, neurosurgery and better supportive care, overall survival rates have been greatly improved in the last two decades from 24 to 82%. Specifically, 70% of patients survive for up to 5 years (Cervoni and Cantore, 1995). However, cranio-spinal radiotherapy causes undesirable long-term sequelae in the young age group, including stunted growth and loss of intellectual function. The use of adjuvant chemotherapy in permitting the reduction of radiotherapy dose is currently being investigated.

A wide range of clinical and biological factors have been studied for their effects on patient survival in the hope of identifying high risk and low risk groups in order to tailor aggressive treatment regimens according to patient prognosis. Among clinical factors studied are patients' age and gender extent of tumour resection and presence of metastasis at diagnosis (Tomita and McLone, 1986; Cervoni and Cantore, 1995; Sure et al, 1995; Weil et al, 1998). The biological disease features studied include expression of p53, loss of heterozygosity (LOH) of chromosome 17, differentiation markers and DNA ploidy (Yasue et al, 1989; Saylors et al, 1991; Badiali et al, 1993; Wang et al, 1998). Thus far, a reliable marker of disease outcome remains to be identified, although it has been noted that the most frequently reported feature in cPNETs is LOH of chromosome 17p, in particular the region containing the p53 gene locus and further telomeric to it (Thomas and Raffel, 1991; Albrecht, 1994). The p53 gene has been reported to be mutated in most cancers (Levine, 1997), and mutant p53 proteins often accumulate in the nucleus because their altered conformation endows them with a property to escape normal degradation.

Our group has previously reported the prognostic value of the immunohistochemical staining intensity of p53 protein in a series of 88 cPNETs (Jaros et al, 1993). In the previous study, immunohistochemistry for p53 was performed without any form of antigen retrieval and high intensity of immunohistochemical staining was significantly associated with poor patient survival. In the current study, immunohistochemistry was performed with microwaving for 85 cases of the original series of cPNETs and 16 new cases. The relationship between the intensity of p53 staining and patient survival was also investigated. As the accumulation of p53 protein in cells could be the result of normal reaction to genotoxic stress by wild-type p53 or of mutations in the p53 gene (Hainaut, 1995) not distinguishable by DO-7 immuno-staining, the coding regions of the p53 gene were sequenced in selective samples to establish the p53 gene status. The expression of other proteins involved in the p53 pathway as downstream mediators of p53 function, i.e. Waf-1, Bax and Bcl-2 (El-Deiry et al, 1993; Miyashita et al, 1994a,b; Miyashita and Reed, 1995), was also studied by immunohistochemistry, and their prognostic value was investigated by survival analyses. Finally, the expression of the above proteins, patients' age, sex and year of diagnosis were entered into a multivariate analysis.

MATERIALS AND METHODS

Patient samples

One hundred and one patients presenting with cPNETs (including 80 medulloblastomas) in the Northern region between 1963 and 1997 were studied, including 85 from the previous study mentioned above (Jaros et al, 1993) and 16 new cases. Patient samples were obtained from surgery, formalin-fixed and embedded in paraffin blocks. All were pre-treatment tissues, i.e. none of the patients had pre-operative radiotherapy or chemotherapy. All patients had attempted surgical removal of the primary tumour which resulted in either partial or total resection. The majority had craniospinal radiotherapy with a boost to the centre of the primary tumour, and some of those treated in the 1990s also received chemotherapy. Diagnosis of the tumours was made by the consultant neuropathologists in post, and the majority reviewed by two neuropathologists. For the purpose of the study, all pathology was reviewed by Professor Perry. Patient information was extracted from a combination of sources: patients' clinical notes obtained from the Medical Records, Newcastle General Hospital, and Middlesbrough General Hospital, and the ‘Children and Young Persons' Malignant Disease Registry’ at the Sir James Spence Institute of Child Health, Royal Victoria Infirmary (RVI), Newcastle Upon Tyne.

Immunohistochemistry: antibodies and controls

A standard immunohistochemical staining method, described previously (Jaros et al, 1993), was performed in conjunction with an antigen retrieval technique. Prior to incubation with the primary antibody, sections were placed in citrate buffer and microwaved at high power for 10 min. Positive and negative controls were set up with every experiment. The same procedures were used for samples and the positive and negative controls, except that the primary antibody was omitted from the negative control. The antibodies used for p53, Waf-1, Bax and Bcl-2 were DO-7 (Novocastra) AB-1 (Oncogene), 13666E (Pharmingen) and 124 (Dako) and diluted at 1 : 50, 1 : 20, 1 : 1200 and 1 : 100, respectively. The control tissue used for p53 was obtained from a glioblastoma multiforme (GBM) paraffin-embedded tumour block. Sections from this block had previously been found to stain positive for DO-7 (Jaros et al, 1993). The control tissue used for Waf-1 staining was breast tumour tissue, and that for both Bax and Bcl-2 was tonsil tissue. The labelling index (LI) for each antibody was defined as the percentage of the number of positive nuclei (p53 and Waf-1), cytoplasm (Bcl-2) or both (Bax) in 1000 tumour cells. The staining intensity (SI) was defined with reference to the positive control (strong) and could be categorised into four groups: strong (A), medium (B), weak (C) and negative (D). Both LI and SI were assessed by two observers using a light microscope, with 95% consensus.

DNA extraction from paraffin-embedded samples, PCR amplification and direct sequencing of exons 2–11 of the p53 gene

Genomic DNA was extracted from eight cases from p53 group A, 11 from groups B and C, and nine from group D for DNA sequencing. The procedures for extracting DNA from paraffin-embedded tissues, PCR amplification and direct sequencing of exons 4–9 of the p53 gene from genomic DNA, using the biotin method for purification of a single-stranded template, and the sequences of the primer pairs, have previously been described in detail (Challen et al, 1992). The sequences for primers corresponding to exons 2, 3, 10 and 11, and a new pair for exon 4, are described in Table 1.

Table 1. Primer pairs used in PCR and DNA sequencing for exons 2, 3, 4, 10 and 11 of the p53 gene; four primers were used for exon 4, to generate products corresponding to two fragments from each half of the exon.

graphic file with name 86-6600151t1.jpg

Open in a new tab

Labelling of PCR product for exon 5 of the p53 gene

This method was applied to all samples to detect the presence of an 18 bp deletion in exon 5 which was identified in one sample during sequencing. A radiolabelled nucleotide α-32P-dATP was incorporated into the PCR products to enable visualisation by acrylamide gel electrophoresis and subsequent phosphorimaging or autoradiography. Slight adjustment was made to the dNTP (deoxynucleotide triphosphate) contents in the PCR mixture, to maintain the dATP concentration within adequate limits for reaction efficiency and fidelity during PCR.

Survival analyses

The Kaplan–Meier method (Graphpad Prism) was used to estimate survival probability as a function of time, and the log-rank test to examine differences in survival between subgroups. Multivariate analysis for p53 SI and LI, age, sex and year of diagnosis (YOD), was performed by Cox's regression using the forward stepwise selection method (SPSS statistical software package).

RESULTS

Immunohistochemical analysis

Detection of p53, Waf-1, Bax and Bcl-2 proteins in normal cerebellar tissue

p53 and Waf-1 were not detectable in normal cerebellar tissues present in 10 tumour sections (Figure 1A, E). Bax was detected in normal cerebellar tissues, mostly in the cytoplasm (Figure 1I). Normal astrocytes were negative whereas reactive astrocytes were moderately stained. The staining of Bcl-2 in normal cerebellar tissue was generally weak, with Purkinje cells and other neurons being weakly or not stained at all (Figure 1M).

Figure 1.

Figure 1

Open in a new tab

(A) Negative p53 staining in a Purkinje cell (P), and in the synaptic areas (S) in the space surrounding the granule cells. (B) Positive p53 staining in glioblastoma multiforme used as positive control. (C) Positive p53 immunostaining in cPNET. (D) Negative staining for p53 in cPNET. (E) Weak Waf-1 staining was observed in Purkinje cell (P) while adjacent granule cells were negative. (F) Strong nuclear staining of Waf-1 in breast carcinoma cells used as positive control. (G) Strong nuclear staining of Waf-1 in cPNET. (H) cPNET negative for Waf-1. (I) Moderate staining of Bax in the cytoplasm and dendrites of Purkinje cell. (J) Strong cytoplasmic staining of Bax in tonsil tissue (positive control). (K) Positive cytoplasmic staining of Bax by 13666E in cPNETs. (L) Negative staining of Bax in cPNET. (M) Postive Bcl-2 staining in the molecular layer of normal cerebellum. (N) Positive cytoplasmic staining of Bcl-2 in tonsil (control tissue). (O) High LI of Bcl-2 staining in cPNET. (P) Bcl-2 staining mainly outside pale islands in desmoplastic medulloblastoma.

Detection of p53, Waf-1, Bax and Bcl-2 proteins in control tissue

Detection of p53, Waf-1, Bax and Bcl-2 in the corresponding control tissue was positive and strong, as expected (Figure 1B, F, J, N).

Detection of p53, Waf-1, Bax and Bcl-2 proteins in cPNETs

In cPNETs both positive and negative staining were observed for all four proteins (Figure 1C, G, K, O). A range of SI and LI was observed, but the majority of tumours showed weak to moderate staining. Both p53 and Waf-1 staining was localised to the nucleus, while Bax staining was observed in nucleus and cytoplasm. The staining of Bcl-2 was localised to the cytoplasm. Examples of negative staining for p53, Waf-1, Bax and Bcl-2 are shown in Figures 1(D, H, L, P) respectively. The distribution of the number of cPNETs in each LI and SI category for each protein is shown in Table 2 and Figure 2 (A–D).

Table 2. The numbers of cPNETs in each SI and LI category for p53, Waf-1, Bax and Bcl-2.

graphic file with name 86-6600151t2.jpg

Open in a new tab
Figure 2.

Figure 2

Open in a new tab

Distribution for LI for p53 (A), Waf-1 (B), Bax (C) and Bcl-2 (D) proteins in cPNETs.

DNA sequencing of the p53 gene and PCR/direct labelling

DNA sequencing identified alterations in exon 5 of the p53 gene in three samples from immunostaining group A, including missense mutations in exon 5 of the p53 gene in two samples (Figure 3A, B), and an in-frame deletion of 18 base pairs, corresponding to codons 275–280, in a third sample. This deletion was confirmed by PCR-direct size analysis (Figure 4A, B) but no evidence of this deletion was found in the other 27 cases analysed by this method. A single base alteration in the DNA sequence of p53 was also detected in intron 6 in a sample which was negative for p53.

Figure 3.

Figure 3

Open in a new tab

Mutations found in the p53 gene in two cPNETs by DNA sequencing. (A) Missense mutation at codon 277 in exon 8 in one cPNET. The panel on the left shows a normal sequence, and the one on the right depicts the sequence harbouring the point mutation at codon 277. (B) An 18-bp region in exon 5 was deleted in one cPNET. The sequence in the panel on the left depicts a normal sequence with nucleotides 13201–13218 highlighted, which are missing in the sample on the right.

Figure 4.

Figure 4

Open in a new tab

The autoradiographs of two acrylamide gels illustrate examples of the bands representing α32P-dATP-labelled PCR products generated from PCR of p53 exon 5. In (A), the band representing the truncated product from the cPNET (sample number 65) harbouring the deletion was viewed against that of another cPNET with a normal sized product and a sequencing ladder of a plasmid. In (B), the products from another cPNETs with a normal exon 5 were run alongside those from sample 65. A normal tissue control (N) was included in the reaction to generate a PCR product of the expected size for comparison.

Prognostic factors in cPNETs

The prognostic value of the accumulation of p53, Waf-1, Bax and Bcl-2 proteins was assessed by both univariate and multivariate analyses, using the Kaplan–Meier method and Cox's regression, respectively. The overall survival of the patients studied (n=101) was 35% at 5 years. The accumulation of p53 protein, which in the majority of cases was wild-type, has significant prognostic value (Figure 5) in this series of cPNETs, with high SI (group A) relating to poor survival (P<0.0001, Log rank test). No significant difference in survival was observed between groups categorised for Waf-1, Bax and Bcl-2 staining. The categories and corresponding P-values for the survival analysis for each protein are shown in Table 3. Other factors, gender, age, and year of diagnosis, were also subjected to both univariate and multivariate analyses, and were found to be independently prognostic in the multivariate analyses (Table 4). However, of all the factors studied in the multivariate analyses, immunohistochemical staining of p53 had the strongest independent prognostic value.

Figure 5.

Figure 5

Open in a new tab

(A) Kaplan–Meier survival analysis found that expression of p53 had significant prognostic value in cPNETs, with a high intensity of DO-7 staining associated significantly with poorest survival (P<0.0001, log rank tested). When samples diagnosed before and after 1979 were analysed separately ((B) and (C) respectively), high intensity of DO-7 staining retained its prognostic significance (P=0.0074 and P<0.0001, respectively). n=number of samples; P=P-value; χ2=chi square value of the test.

Table 3. Summary of results of univariate analyses for the expression of p53, Waf-1, Bcl-2, Bax, age, gender and year of diagnosis in cPNETs.

graphic file with name 86-6600151t3.jpg

Open in a new tab

Table 4. Multivariate analysis results for the SI of p53, age, gender and year of diagnosis in cPNETs. p53 SI has the strongest prognostic value.

graphic file with name 86-6600151t4.jpg

Open in a new tab

DISCUSSION

p53 protein expression was detected in the majority of the 101 cPNETs in this study, but only 12 of these (11.9%) had high staining intensity. The level of staining of p53 in the present study, which employed microwaving for antigen retrieval in the immunohistochemistry was consistent with that of a previous study (Jaros et al, 1993), in which no antigen retrieval was employed. DNA sequencing results indicated that p53 gene mutations in this series of cPNETs were infrequent, which was consistent with the findings from other studies (Saylors et al, 1991; Adesina, 1994) and could explain the high sensitivity of medulloblastoma cells to radio therapy (Chang et al, 1969).

The low incidence of p53 gene mutations in these cPNETs suggested that the p53 protein in these tumours was likely to be wild-type and functional. This was consistent with the significantly positive relationship between the expression of p53 and Bax (Table 5) which is a known target of p53 transcriptional activity (Miyashita and Reed, 1995). The expression of wild-type p53 in cPNETs may reflect a normal cellular response to the stressful microenvironment in the tumours, including nutrient deprivation, hypoxia and redox imbalance which would induce and stabilise WTp53 up-regulation (Graeber et al, 1994; An et al, 1998). Normal cells in such conditions would have undergone apoptosis, but it is likely that in some of these tumours, apoptosis was inhibited by the presence of Bcl-2. On the other hand, the expression of Waf-1 did not relate to that of p53 in these tumours (Table 5) which might not be unexpected, as Waf-1 expression is not exclusively controlled by p53 (Halevy et al, 1995; Russo et al, 1995; Liu et al, 1996). However, disturbance in the expression of Waf-1 protein in cells which over-express non-functional wild-type p53 has been reported in gliomas and glioma cell lines (Pykett et al, 1998) and the lack of relationship between the expression of these two proteins has also been reported in colorectal carcinoma (Slebos et al, 1996) and breast carcinoma (Barbareschi et al, 1996).

Table 5. The relationship between the expression of p53, Waf-1, Bax and Bcl-2 in cPNETs.

graphic file with name 86-6600151t5.jpg

Open in a new tab

Contrary to p53 and Bax, the positive relationship between the expression of p53 and Bcl-2 proteins in the cPNETs (Table 5) was unexpected, as an inverse correlation between the expression of the two proteins would have been predicted, based on the current understanding of the suppressive function of p53 on Bcl-2 transcription (Seto et al, 1992; Miyashita et al, 1994a,b). This observation could be the result of induction of p53 in response to the elevated levels of Bcl-2, which could in turn be the result of a factor or mechanism that has given rise to the tumours. A likely candidate for this factor or mechanism was growth factor/receptor or oncogene de-regulation, as some of the tumours in this study have been found to over-express erbB2, a member of the epidermal growth factor receptor or EGFR family (Gilbertson et al, 1997, 1998).

In conclusion, the present study has shown that a high level of p53 protein in cPNETs measured by immunostaining intensity was associated with poor patient survival, supporting the findings of a previous study, and appeared to reflect the aggressiveness of the tumours. Sequencing results and the overall positive relationship between the expression of p53 and Bax pointed to the possibility that the p53 protein in the current series of cPNETs was wild-type and functional, except in the subset of tumours which expressed high levels of Bcl-2. In addition, maleness, young age at diagnosis and diagnosis before 1979 were all independent indicators of poor prognosis. Further research work, including functional assays involving reporter systems in cell lines and studies investigating the mechanisms underlying the expression of Bcl-2 in cPNETs, will clarify the functional status of p53 in central primitive neuroectodermal tumours.

Acknowledgments

This study was sponsored by the North of England Children's Cancer Research Campaign. Patient survival data was retrieved from the Children and Young Person's Malignant Disease Registry with the help of Lorna More. Many thanks to the staff at the Neuropathology Department of the Newcastle General Hospital.

References

  1. AdesinaA1994p53 gene mutation and Mdm2 gene amplification are uncommon in medulloblastoma Cancer Res 5456495651 [PubMed] [Google Scholar]
  2. AlbrechtS1994Microsatellite analysis of loss of heterozygosity on chromosomes 9q 11p and 17p in medulloblastomas Neuropathol Applied Neurobiol 207481 [DOI] [PubMed] [Google Scholar]
  3. AnWGKanekalMSimonMCMaltepeEBlagosklonnyMVNeckersLM1998Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha Nature 392405408 [DOI] [PubMed] [Google Scholar]
  4. BadialiMIolasconALodaMScheithauerBWBassoGTrentiniGPGiangasperoF1993p53 gene mutations in medulloblastoma. Immunohistochemistry gel shift analysis and sequencing Diagn Mol Pathol 22328 [PubMed] [Google Scholar]
  5. BarbareschiMCaffoODoglioniCFinaPMarchettiAButtittaFLeekRMorelliLLeonardiEBevilacquaGDalla PalmaPHarrisAL1996p21WAF1 immunohistochemical expressin in breast carcinoma: correlations with clinicopathological data oestrogen receptor status MIB1 expression p53 gene and protein alterations and relapse-free survival Br J Cancer 74208215 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. CervoniLCantoreG1995Medulloblastoma in pediatric age: a single instituiton review of prognostic factors Child's Nerv Syst 118085 [DOI] [PubMed] [Google Scholar]
  7. ChallenCLunecJWarrenWCollierJBassendineMF1992Analysis of TP53 tumour suppressor gene in hepatocellular carcinomas from Britain Hepatology 1613621366 [DOI] [PubMed] [Google Scholar]
  8. ChangCHHousepianEMHerbertC1969An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas Radiology 9313511359 [DOI] [PubMed] [Google Scholar]
  9. de VitaVTHellmanSRosenbergSA1982Cancer: Principles and Practice of OncologyPhiladelphia: J.B. Lippincott Co [Google Scholar]
  10. El-DeiryWSTokinoTVelculescuVELevyDBParsonsRTrentJMLinDMercerWEKinzlerKWVogelsteinB1993WAF1 a potential mediator of p53 tumor suppression Cell 75817825 [DOI] [PubMed] [Google Scholar]
  11. GilbertsonRJCliffordSCMacMeekinWMeekinWWrightCPerryRHKellyPPearsonADLunceJ1998Expression of the ErbB-neuregulin signaling network during human cerebellar development: implication for the biology for the biology of medulloblastoma Cancer Res 5839323941 [PubMed] [Google Scholar]
  12. GilbertsonRJPerryRHKellyPJPearsonADLunecJ1997Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma Cancer Res 5732723280 [PubMed] [Google Scholar]
  13. GraeberTGPetersonJFTsaiMMonicaKFornaceAJJGiacciaAJ1994Hypoxia induces accumulation of p53 protein but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status Mol Cell Biol 1462646277 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. HainautP1995The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival Curr Opin Oncol 77682 [PubMed] [Google Scholar]
  15. HalevyOBennettGNovitchBGSpicerDBSkaperSXRheeJHannonGJBeachDLassarAB1995Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD Science 26710181021 [DOI] [PubMed] [Google Scholar]
  16. JarosELunecJPerryRHKellyPJPearsonADJ1993p53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis Br J Cancer 68801807 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. LevineAJ1997p53 the cellular gatekeeper for growth and division Cell 88323331 [DOI] [PubMed] [Google Scholar]
  18. LiuYMartindaleJLGorospeMHolbrookNJ1996Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase Cancer Res 563135 [PubMed] [Google Scholar]
  19. MiyashitaTHarigaiMHanadaMReedJC1994aIdentification of a p53-dependent negative response element in the bcl-2 gene Cancer Res 5431313135 [PubMed] [Google Scholar]
  20. MiyashitaTKrajewskiSKrajdwskaMWangHGLinHKLiebermannDAHoffmanBReedJC1994bTumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo Oncogene 917991805 [PubMed] [Google Scholar]
  21. MiyashitaTReedJC1995Tumor suppressor p53 is a direct transcriptional activator of the human bax Gene Cell 80293299 [DOI] [PubMed] [Google Scholar]
  22. PykettMJAzzamEDahlbergWLittleJB1998Differential p53 p21 mdm2 and Rb regulation in glioma cell lines that overexpress wild-type p53 Int J Oncol 13213216 [DOI] [PubMed] [Google Scholar]
  23. RobertsROLynchCFJonesMPHartMN1991Medulloblastoma: a population-based study of 532 cases J Neuropathol Exper Neurol 50134144 [DOI] [PubMed] [Google Scholar]
  24. RussoTZambranoNEspositoFAmmendolaRCiminoFFiscellaMJackmanJO'ConnorPMAndersonCWAppellaE1995A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress J Biol Chem 2702938629391 [DOI] [PubMed] [Google Scholar]
  25. SaylorsRLISidranskyDFriedmanHSBignerSHBignerDDVogelsteinBBrodeurGM1991Infrequent p53 gene mutations in medulloblastomas Cancer Res 5147214723 [PubMed] [Google Scholar]
  26. SetoEUshevaAZambettiGPMomandJHorikoshiNWeinmannRLevineAJShenkT1992Wild-type p53 binds to the TATA-binding protein and represses transcription Proc Natl Acad Sci 891202812032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. SlebosRJBaasIOClementMPolakMMulderJWvan den BergFMHamiltonSROfferhausGJ1996Clincial and pathological association with p53 tumour suppressor gene mutations and expression of p21 WAF/CIP1 in colorectal carcinoma Br J Cancer 74165171 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. SureUBerghornWJBertalanffyHWakabayashiTYoshidaJSugitaKSeegerW1995Staging scoring and grading of medulloblastoma Acta Neurochir 1325965 [DOI] [PubMed] [Google Scholar]
  29. ThomasGARaffelC1991Loss of Heterozygosity on 6q 16q and 17p in human central nervous system primitive neuroectodermal tumors Cancer Res 51639643 [PubMed] [Google Scholar]
  30. TomitaTMcLoneDG1986Medulloblastoma in childhood: results of radical resection and low-dose neuraxis radiation therapy J Neurosurg 64238242 [DOI] [PubMed] [Google Scholar]
  31. WangWKumarPWangWWhalleyJSchwarzMMaloneGHaworthAKumarS1998The mutation status of PAX3 and p53 genes in medulloblastoma Anticancer Res 18849853 [PubMed] [Google Scholar]
  32. WeilMDLambornKEdwardsMSWaraWM1998Influence of a child's sex on medulloblastoma outcome JAMA 27914741476 [DOI] [PubMed] [Google Scholar]
  33. YasueMTomitaTEngelhardHGonzalaz-CrussiFMcLoneDGBauerKD1989Prognostic importance of DNA ploidy in medulloblastoma of childhood J Neurosurg 70385391 [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES